Ginkgo Bioworks Holdings Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.4. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | VWO | |
|---|---|---|
Market Cap | $505.73M | — |
Sector | Health | — |
52-Week High | $16.14 | $61.24 |
52-Week Low | $5.48 | $51.20 |
Enterprise Value | $607.68M | — |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
VWO, the Vanguard FTSE Emerging Markets ETF, trades at $60.41, up 0.13% on the day, with a bullish technical signal from moving averages and a neutral reading from oscillators. The fund's low expense ratio of 0.06% and focus on emerging markets attract institutional inflows, as seen in recent 13F filings. Recent news highlights strong capital flows into emerging market ETFs and comparisons with peers on cost and diversification.
The outlook for VWO is supported by record inflows and favorable expense ratios, but risks include concentrated exposure to developing economies and currency volatility. Analyst sentiment is generally positive due to diversification benefits and cost efficiency, though geopolitical and economic uncertainties in emerging markets pose significant headwinds for sustained growth.
Trailing returns across standard periods
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →